Pune, India, July 2018 /MRFR Press Release/- Market Research Future has published a half-cooked research report on the global overactive bladder treatment market.
Overactive Bladder (OAB) is typically characterized by urinary urgency, frequency, and nocturia. The growing prevalence of Overactive Bladder (OAB) with the growing geriatric population and rising occurrences of neurological diseases are major factors driving the growth of the market. Additionally, according to the Advanced Urology Institutes in 2015, 1/3rd of men and women between the ages of 30 to70, had lost bladder control. Moreover, the growing development of innovative intravesical therapies and increasing commercialization activities by pharma companies are expected to propel the market growth.
On the other hand, lack of awareness in the developing countries and undesired systemic effects of some current treatment option may hamper the growth of the market during the forecast period.
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is expected to dominate the market in the Americas owing to the increasing geriatric population, growing incidences of OAB and urinary incontinence symptoms, and the availability of healthcare coverage systems such as Medicare. For instance, as per the data stated by the National Association for Continence (NAFC), approximately 25 million adult Americans experience transient or chronic urinary incontinence. It also stated that 75 to 80% of these sufferers are women. Europe is expected to hold the second position in the market owing to the increasing healthcare expenditure, growing occurrences of OAB, and the availability of reimbursement options. Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of OAB, rising geriatric population, and growing awareness about overactive bladder condition. Furthermore, the Middle East and Africa is likely to hold the least share in the global overactive bladder treatment market.
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease. On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others. The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others. On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson's disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and the overactive bladder in other disorders.
Global Overactive Bladder Treatment Key Players
Some of the prominent players in the market are Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Allergan, Plc., Mylan N.V., Endo International Plc, Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Aurobindo Pharma Limited, Johnson & Johnson, Intas Pharmaceuticals Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., Medtronic PLC, Cogentix Medical, Inc., and others.